logo
Menu

This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Human acellular vessel for vascular access for haemodialysis in end-stage renal disease

< Back

Human acellular vessel for vascular access for haemodialysis in end-stage renal disease

Drugs

Renal Disease and Urology

November 2019


The Human acellular vessel (HAV) is in clinical development to provide vascular access for haemodialysis patients with end-stage renal disease (ESRD). ESRD is a long-term irreversible condition where the kidneys do not work as well as they should as a result of chronic kidney disease. There is no cure for kidney failure and patients with this condition requires haemodialysis or a renal transplant for survival. Haemodialysis works by taking blood from the body and cleaning it through a machine to remove the toxins. Blood is filtered before being returned to the body. Vascular access is a way to reach the blood during haemodialysis.
The HAV is a bio-engineered vascular tube for dialysis access in patients with ESRD. It utilises human vascular cells to form a mechanically strong, engineered tube similar to native blood vessels. The HAV is among the first generation regenerative medicine aiming to generate artificial biological structures used to repair or replace damaged tissues and organs. If licensed the HAV will provide a treatment option for patients to use a prosthesis for vascular access in haemodialysis patients with ESRD.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Article



 

Connect to the Innovation Observatory

Twitter

Load More Related Posts

Get Alerts